Quantcast
Connect with us

Devonta Freeman tells Buccaneers to deal directly with him

Devonta Freeman, Buccaneers

Maybe Devonta Freeman’s price isn’t too high for the Tampa Bay Buccaneers after all.

The 28-year-old running back took to Twitter on Thursday night to send a message — if Tampa Bay wants to negotiate a deal with him, they can reach out to him directly. The tweet comes just hours after head coach Bruce Arians confirmed the team’s interest in Freeman, but also stated that his price was too high for Tampa Bay.

The former two-time Pro Bowl running back remains a free agent into the month of June. He is coming off of a rough 2019 season in which he ran for just 656 yards on 3.6 yards per carry. His two rushing touchdowns also represented his lowest total for a full season since his rookie campaign in 2014 when he was a reserve running back.

Freeman’s disappointing 2019 season followed after an injury-plagued 2018 campaign in which he was placed on injured reserve due to a groin injury.

Despite the past two years being a wash for Freeman, there has still been interest in the free agency market for the veteran running back.

Mike Silver of NFL Media had previously reported that Freeman believes he’s worth more than he’s being offered. Furthermore, Silver also states that he’s willing to sit out the season if his price isn’t met.

“Freeman believes he is worth more than what was being offered and has insisted he is willing to . . . skip the season if his number isn’t met,” Silver writes. “Freeman has invested his money well and saved much of the income he’s earned thus far. Financially, he does not have to play. His current mentality is that he won’t play if he doesn’t get an offer that reflects what he believes his value is.”

Freeman’s recent tweet seems to go against Arians’ comments and what Silver is reporting. It also indicates that Tampa Bay has yet to actually reach out to the running back himself.

We’ll see if the Buccaneers and Freeman actually discuss a deal and are able to come to an agreement after this latest development.